Journal
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 172, Issue 12, Pages 1487-1490Publisher
AMER THORACIC SOC
DOI: 10.1164/rccm.200504-613PP
Keywords
antituberculosis drugs; nanoparticles; tuberculosis therapy
Categories
Funding
- NIAID NIH HHS [R21AI055284] Funding Source: Medline
Ask authors/readers for more resources
Nanoparticle-based drug delivery systems have considerable potential for treatment of tuberculosis (TB). The important technological advantages of nanoparticles used as drug carriers are high stability, high carrier capacity, feasibility of incorporation of both hydrophilic and hydrophobic substances, and feasibility of variable routes of administration, including oral application and inhalation. Nanoparticles can also be designed to allow controlled (sustained) drug release from the matrix. These properties of nanoparticles enable improvement of drug bioavailability and reduction of the dosing frequency, and may resolve the problem of nonadherence to prescribed therapy, which is one of the major obstacles in the control of TB epidemics. This article highlights some of the issues of nano-technology relevant to the anti-TB drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available